Gilead’s India Patent Snag May Spur Low-Cost Sovaldi Copies
This article is for subscribers only.
The Indian patent office’s rejection of a key patent claim for Gilead Sciences Inc.’s Hepatitis C treatment Sovaldi may pave the way for more low-cost copies in the country, potentially aiding local companies including Natco Pharma Ltd.
The New Delhi patent office this week rejected one of the patent claims for Sovaldi. Sovaldi’s $84,000 price tag for a 12-week course in the U.S. has drawn criticism from patient advocates.